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Abstract
Objective It is sometimes difficult to assess I-131 lung
uptake at the initial I-131 therapy because of strong arti-
facts from I-131 uptake in the thyroid bed. The aim of this
study was to analyze the lung uptake at the second I-131
therapy for lung metastasis in patients who did not have
lung uptake at the initial therapy from differentiated thy-
roid carcinoma (DTC). Then, we also analyzed the rela-
tionship between the initial lung uptake and short-term
outcome after I-131 therapies.
Methods This study included 62 DTC patients with lung
metastasis. The patients were classified into 2 groups
according to the lung uptake at the initial I-131 therapy
such as patients with lung uptake (positive uptake group
n = 31) and those without lung uptake (negative uptake
group n = 31). The lung uptake was analyzed at the second
therapy in both groups. The short-term outcome was also
analyzed based on the CT findings of lung metastasis size
and serum thyroglobulin level between the two groups.
Results The positive uptake group showed positive lung
uptake at the second therapy in 23 patients (74 %), whereas
none of negative uptake group showed any lung uptake at
the second therapy (P \ 0.01). The positive uptake group
significantly decreased in the size of lung metastasis from
the initial therapy to the second therapy (20.0 ± 11.7 to
16.6 ± 9.6 mm, P \ 0.01) with further decrease after the
second therapy (P \ 0.05). The serum thyroglobulin level
was also significantly decreased from the initial therapy to
the second therapy (4348 ± 7011 to 2931 ± 4484 ng/ml,
P \ 0.05). In contrast, the negative uptake group signifi-
cantly increased in the size of lung metastasis from the
initial therapy to the second therapy (17.3 ± 12.2 to
19.9 ± 14.3 mm, P \ 0.01) with further increase after the
second therapy (P \ 0.01).
Conclusion No patients without lung uptake at the initial
I-131 therapy showed lung uptake at the second therapy, or
showed treatment effect. Therefore, second I-131 therapy
for these patients with initially negative lung uptake should
be considered cautiously.
Keywords Thyroid cancer  Lung metastasis  I-131
therapy  Radioiodine therapy
Introduction
The lung is a common organ of metastasis from differenti-
ated thyroid carcinoma (DTC). Respiratory failure is the
most common cause of death [1]. 131I therapy is a widely
accepted treatment for patients with lung metastasis from
DTC. A number of studies have reported that 131I-avid lung
metastasis is curable and has an excellent prognosis. In
contrast, 131I-non-avid lung metastasis has a relatively poor
prognosis with high thyroglobulin levels [2–5]. Therefore,
patients without lung uptake on the initial therapy may need
131I retreatment. But interpretation of 131I uptake in the
metastasis by planar image is often challenging because of
artifacts from strong 131I uptake in the thyroid bed [6]. Fur-
thermore, as the initial 131I therapy, 131I uptake in lung
metastasis may be inhibited by the strong uptake of the
thyroid bed. We hypothesized that lung uptake may appear
on the second 131I therapy for these patients without lung
uptake at the initial 131I therapy due to the lack of further
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uptake by the thyroid bed after thyroid bed ablation.
Accordingly, we performed two 131I therapies regardless of
uptake in lung metastasis at the initial therapy. However, the
treatment effect of the second therapy remains unclear. The
aim of this study was to investigate the relationship between
lung uptake and short-term outcome after the initial 131I
therapy for lung metastasis from DTC. We also evaluated the
lung uptake on the second 131I therapy for patients without
lung uptake at the initial high-dose 131I therapy.
Materials and methods
Study subjects
Patients who had lung metastasis and underwent total thy-
roidectomy for DTC, and had at least two 131I therapies were
retrospectively included in this study. The 131I treatment
dose ranged from 100 to 150 mCi in each treatment [7–10].
Patients whose serum thyroid-stimulating hormone (TSH)
level was less than 30 mU/l on the second therapy were
excluded because 131I uptake in lung metastasis might have
been decreased by low TSH level. As a result, 62 patients
were included in this study from July 2002 to May 2011.
I-131 therapy and I-131 imaging
Patients had low-iodine diet and discontinuation of thyroxine
3 weeks prior to 131I treatment. These patients had whole-
body scan 2–8 days after 131I treatment. 131I whole-body
scan was performed using a Millennium MG gamma camera
(General Electric; Elgems, Tirat Carmel, Israel) with high-
energy collimators [11]. Two nuclear physicians (one with
19 years’ experience, and another with 10 years’ experi-
ence) visually interpreted 131I whole-body scan images by
consensus with blinded manner of patients’ clinical infor-
mation. The positive lung 131I uptake was defined as follows.
The lung uptake was positive when uptake was higher than
the background physiological mediastinum uptake. We
defined the patients with lung uptake at first therapy as the
‘‘positive’’ group. Those without 131I lung uptake were
defined as the ‘‘negative’’ group. The 131I lung uptakes at the
second therapy were analyzed for the two groups.
Effects of I-131 treatments
We evaluated 131I therapeutic effects based on the size of
the metastatic lung nodule using computed tomography
(CT) and serum thyroglobulin under TSH stimulation. The
size of the lung nodule was assessed according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.1 [12, 13]: We analyzed sum of a maximum
longest (SML) diameter of 2 lung nodules on CT. SML was
compared between the initial therapy and after the second
therapy. Serum thyroglobulin levels at both the initial and
second therapy were measured to compare the change from
the initial therapy.
Statistical analysis
Values are addressed mean ± SD. The frequency of lung
uptake at initial 131I therapy and second 131I therapy was
analyzed by Fisher’s exact test. The changes of nodule size
and thyroglobulin were analyzed using the Wilcoxon
Matched-Pair Signed-Rank Test. Tumor response evalua-
tion according to RECIST criteria was analyzed by Coch-
ran–Armitage test. P values of less than 0.05 were
considered to indicate statistical significance.
Results
Patient characteristics
Characteristics of the 62 study patients are shown in Table 1.
Fifty-two patients were papillary carcinoma. 8 patients were
follicular carcinoma. With remaining two patients, 1 was
mixed papillary follicular carcinoma and another one was
poorly differentiated carcinoma, respectively. Twenty-two
patients were male and 40 were female. The initial admin-
istration dose of 131I was 5.18 ± 0.54 GBq (mean ± stan-
dard deviation), and ranged from 3.56 to 5.55 GBq. The time
interval from the initial therapy to the second therapy was
287 ± 187 months, ranging from 147 to 1376 days. Follow-
up CT was performed 336 ± 221 days after the second
therapy. There was no patient who had new lesion in other
organs within follow-up period.
After the initial therapy, 31 patients were assigned to the
positive uptake group (papillary carcinoma 21, follicular
carcinoma 8, mixed papillary follicular carcinoma 1, and
poorly differentiated carcinoma 1). Other 31 patients were
defined as the negative uptake group (papillary carcinoma
31). There were no significant differences between these
two groups in terms of administration dose (5.19 ± 0.54
vs. 5.12 ± 0.56 GBq), serum TSH level (85.9 ± 52.0 vs.
77.5 ± 38.9 mIU/l), and size of lung nodule (20.0 ± 11.7
vs. 18.0 ± 15.5 mm). Positive uptake group was signifi-
cantly younger than that in negative uptake group
(P \ 0.05). The serum thyroglobulin level in the positive
uptake group was significantly higher than that in the
negative uptake group (P \ 0.05) (Table 1).
I-131 lung uptake
In the positive uptake group, 23 patients (74 %) showed
lung uptake on the second therapy (papillary carcinoma 15,
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follicular carcinoma 7, poorly differentiated carcinoma 1),
and 8 patients did not have lung uptake (papillary carci-
noma 6, follicular carcinoma 1, mixed papillary follicular
carcinoma 1). In the negative uptake group, all patients did
not have any positive lung uptake on the second therapy
(P \ 0.01) (Fig. 1).
Therapeutic response to I-131
In the positive uptake group, 28 patients underwent CT at
both initial and second therapy, but three patients were
excluded due to the absence of an applicable CT. Among
total 25 patients, these patients significantly reduced the
average size of metastatic lung nodule at the second ther-
apy imaging compared to before the initial treatment
(20.0 ± 11.7 to 16.6 ± 9.6 mm, P \ 0.01) (Fig. 2). Six-
teen patients had additional follow-up CT studies after the
second therapy (Fig. 3). The size of the lung nodule tended
to decrease from 16.4 ± 5.8 mm at the second therapy to
14.7 ± 6.6 mm at the follow-up CT (324 ± 244 days after
the second therapy) (P \ 0.05). Serum thyroglobulin
obtained from all 31 patients significantly decreased from
initial study to the second therapy (4348 ± 7011 to
2931 ± 4484 ng/ml, P \ 0.05) (Fig. 4).
All negative uptake group (n = 31) underwent CT at
both the initial and second therapy. The size of lung nodule
was significantly increased from initial therapy to second
therapy (17.3 ± 12.2 to 19.9 ± 14.3 mm, P \ 0.01)
(Fig. 2). In the 17 cases that were successfully followed up
after the second therapy, the size of lung nodule had sig-
nificantly increased from second therapy to follow-up CT
(375 ± 174 days later) (22.2 ± 18.3 to 27.9 ± 21.9 mm,
P \ 0.01) (Fig. 3). In all patients of the negative
uptake group (n = 31), serum thyroglobulin tended to
increase from the initial therapy to the second therapy
(1297 ± 3351 to 2167 ± 6812 ng/ml, NS) (Fig. 4).
We investigated the tumor response from the initial
therapy to the second therapy using RECIST. In the
positive uptake group, 7/28 patients were assessed as PR
and the remaining 21 patients were defined as SD. In the
negative uptake group, on the other hand, 24/31 patients
were SD, and 7/31 were PD. Patients with positive lung
uptake showed significantly higher in PR patients com-
pared to negative uptake group, and negative uptake
group showed significantly higher in PD patients com-
pared to positive uptake group (P \ 0.001). There was no
patient with CR or PR in the negative uptake group
(Table 2).
Discussion
This research revealed new results: namely, that patients
without lung uptake at the initial 131I therapy had no lung
uptake at the second therapy. None of them showed any
therapeutic effect (CR or PR) of the second therapy. These
results suggest that second 131I therapy for patients without
lung uptake at the initial therapy is less effective.
We hypothesized that lung uptake on the initial therapy
might be inhibited because of strong uptake of the thyroid
bed, or lung uptake might be interpreted as negative
because of the artifact from accumulation of thyroid bed.
Fig. 1 Flow chart of lung uptake of 131I at the initial therapy and at
the second therapy
Table 1 The characteristics of patients in the positive and negative















131I dose (GBq) 5.19 ± 0.54 5.16 ± 0.56 NS***
Age 54.4 ± 14.2 62.5 ± 10.4 \0.05***
TSH (mIU/l) 85.9 ± 52.0 77.5 ± 38.9 NS***
Thyroglobulin
(ng/ml)




20.0 ± 11.7 18.0 ± 15.5 NS***
TSH Thyroid-stimulating hormone, CT computed tomography
* Poorly differentiated carcinoma or papillary with follicular
carcinoma
** Fisher’s exact test
*** Mann Whitney U test
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Fig. 2 The sum of lung
metastatic nodule. a In the
positive uptake group, lung
metastases became significantly
smaller after the initial and the
second therapy by Wilcoxon
Matched-Pair Signed-Rank
Test. b Metastatic lung nodules
became significantly enlarged
after the initial and the second
therapy in the negative uptake
group
Fig. 3 a A 45-year-old female with lung metastases from papillary
carcinoma of the thyroid. (a) CT image at the initial therapy shows
multiple lung metastases. (b) In the initial therapy, a post-therapeutic
131I scan suggested high uptake both in the thyroid bed and lower
lung. (c) CT at the second therapy demonstrated that lung metastasis
had got smaller. (d) In the second therapy, 131I scan showed also high
uptake in lower lung. (e) Thirteen months after the second therapy,
the lung nodule was further reduced on CT. Thyroglobulin at the
initial therapy was 2768 ng/ml, and that at the second therapy had
fallen to 2383 ng/ml. b A 53-year-old female with lung metastases
from papillary carcinoma of the thyroid. (a) CT image at the initial
therapy demonstrates multiple lung metastases. (b) Post-therapeutic
131I scan at the initial therapy showed high uptake in the thyroid bed
but no uptake in the lung. Physiological uptake in intestinum is
shown. (c) The metastatic nodule had grown larger on the CT at the
second therapy. (d) At the second therapy, the 131I scan showed
uptake in intestinum and salivary glands physiologically, but no lung
uptake even though the thyroid bed uptake had disappeared. (e) CT
image 21 months after the second therapy. Lung metastases had
progressed in size. Serum thyroglobulin was increased from 844 ng/
ml at the initial therapy to 2352 ng/ml at the second therapy
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We expected that since the thyroid bed signal disappears
after the initial therapy, lung uptake might possibly appear
at the second therapy, even for those with no signal ini-
tially. However, none of the cases actually showed positive
lung uptake in the second therapy. Two reasons could be
considered for our results. First, all patients underwent total
thyroidectomy with only the minimal amount of thyroid
bed remaining. Therefore, the uptake in small thyroid bed
did not likely inhibit lung uptake. A large remnant thyroid
produces a strong artifact on 131I scan, and lung uptake of
131I could be false negative. However, we did not experi-
ence any case with a strong artifact from the thyroid bed. If
there is strong artifact from thyroid bed, single photon
emission computed tomography (SPECT/CT) may improve
detection of lung uptake [14, 15]. Second, we administer a
‘‘high’’ dose 131I (5.18 ± 0.54 GBq) at the initial therapy.
Our administration dose is within the recommended dose
range for metastasis (3.7–11.1 GBq), and it is higher than
the recommended dose for ablation (3.7 GBq) [7–10]. In
addition, a high-dose 131I scan could enhance detectability
of lung uptake. Although the maximum administration
dose for patients with metastasis is 11.1 GBq, it is limited
to 5.55 GBq in our institution. Even so, the 131I dose in this
study was considered to be enough for transfer beyond the
remnant thyroid to the lung.
In our study, a therapeutic effect was clarified for the
positive uptake group for the initial therapy with a decrease
in tumor size and serum thyroglobulin levels. In contrast,
the negative uptake group showed an increase in lung
metastasis size, with increased serum thyroglobulin levels.
Some papers have reported that cases with lung uptake on
131I therapy have better prognosis than the cases without
lung uptake [7–10, 16]. Although we could not analyze
long-term prognosis, the outcome of lung metastasis in our
study is consistent with these reports.
It is uncertain whether the outcome for the negative
uptake group may be better with second 131I therapy than
that without second therapy. No previous report has sug-
gested an answer to this question. However, our results
indicated that lung metastasis may progress with increases
in size and serum thyroglobulin levels for these patients.
Because 131I therapy has some side effects such as hypo-
thyroidism, sialitis, bone marrow depression, and so on, the
indication for second therapy for such patients should be
Table 2 Response evaluation
of the initial therapy according
to RECIST
CR complete response, PR
partial response, SD stable






CR (Disappearance of all target lesions) 0/28 0/31
PR (C30% decrease in the sum of the longest




SD (neither PR or PD) 21/28 24/31
PD (C20% increase in the sum of the longest
diameter of target lesions compared with the
smallest-sum longest diameter recorded)
0/28 7/31
Fig. 4 Thyroglobulin level at
the 131I therapy. a In the
positive uptake group,
thyroglobulin at the second
therapy significantly decreased
from that at the initial therapy
by Wilcoxon Matched-Pair
Signed-Rank Test.
b Thyroglobulin at the second
therapy tended to increase from
that at the initial therapy in the
negative uptake group
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considered carefully. A prospective randomized controlled
study is warranted to clarify this point.
Some reports advocate that 18F-fluoro-deoxy-D-glucose
positron emission tomography (FDG-PET) is especially
effective for patients with elevated thyroglobulin levels and
normal radioiodine whole-body scan [17]. Furthermore,
Shiga [11] reported that FDG-PET and 131I scintigraphy
provided complementary information. It is possible that
FDG-PET can give useful information for decisions on the
indications for an initial or second 131I therapy. But we did
not analyze FDG-PET findings because of the small
number of patients in this study. This is also an issue for
the future.
This study has several limitations. First, it is retrospec-
tive in nature. Patients who did not undergo second therapy
due to their activity of daily life or other background were
excluded, even when lung uptake was shown at the initial
therapy. Therefore, selection bias is considerable. Second,
the number of patients was limited. If we experience more
cases, a case with lung uptake on the second therapy might
appear. Even so, these cases may be very rare. Therefore,
we can conclude that the indications for second therapy for
these cases are rare. The third is the short-term follow-up
(324 ± 244 days after the second therapy in the positive
uptake group, and 375 ± 174 days later in the negative
uptake group). Because progression of DTC is slow, more
long-term follow-up or survival rate analysis is needed for
more accurate evaluation.
131I avidity for lung metastasis is usually evaluated by
diagnostic scan with a tracer dose of 131I, and it is
unpredictable by other modalities [18–20]. However, our
cases did not undergo a diagnostic scan. One reason is that
in diagnostically negative 131I uptake patients who have a
positive post-treatment scan, high-dose 131I therapy can be
used as a diagnostic tool to identify tumor location, and a
therapeutic effect may be present in individual cases
[2–5]. Another reason is that Japan is a region of excessive
iodine intake because of seafood. Therefore, a low-iodine
diet is difficult for Japanese, and the effort required for our
institution to provide a low-iodine diet in the hospital for
1 week before 131I therapy was out of proportion to the
benefit of such a diet prior to diagnosis. For these rea-
sons, we did not perform diagnostic scans. Alternatively,
high-dose 131I therapy was used as a tool for sensitive
diagnosis.
In conclusion, patients with lung metastasis from dif-
ferentiated thyroid carcinoma had a poorer outcome when
the initial 131I therapy did not show lung uptake than those
with positive lung uptake. No patients without lung uptake
at the initial 131I therapy showed lung uptake at the second
therapy. Therefore, the second 131I therapy for these
patients should be considered cautiously considering the
side effects of 131I therapy.
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